AQP4 antibodies in neuromyelitis optica: Diagnostic and pathogenetic relevance

Nature Reviews Neurology

Volumn 6, Issue 7, 2010, Pages 383-392

  Jarius, Sven ^a   Wildemann, Brigitte ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AQUAPORIN 4; B CELL ACTIVATING FACTOR; EPITOPE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTAMIC ACID; INTERLEUKIN 6; METHYLPREDNISOLONE; PREDNISONE; PROTEIN ANTIBODY; PROTEIN S100B; RITUXIMAB; ANTIBODY; AQP4 PROTEIN, HUMAN; BIOLOGICAL MARKER; GLUCOSE;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ANTIBODY TITER; ASTROCYTE; B LYMPHOCYTE; BLOOD BRAIN BARRIER; CELL DEATH; DIAGNOSTIC TEST; DISEASE ACTIVITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG TARGETING; HOMEOSTASIS; HUMAN; IMMUNOPATHOGENESIS; INFECTION; MULTIPLE CYCLE TREATMENT; MYELOOPTIC NEUROPATHY; NEUROPATHOLOGY; NONHUMAN; PASSIVE IMMUNIZATION; PATHOPHYSIOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEPLETION; PROTEIN FUNCTION; REVIEW; SENSITIVITY AND SPECIFICITY; SEROLOGY; TREATMENT OUTCOME; TREATMENT RESPONSE; IMMUNOLOGY; METABOLISM; NEUROMYELITIS OPTICA; PHYSIOLOGY; PREDICTIVE VALUE;

ANTIBODIES; AQUAPORIN 4; BIOLOGICAL MARKERS; BLOOD-BRAIN BARRIER; GLUCOSE; HOMEOSTASIS; HUMANS; NEUROMYELITIS OPTICA; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 77954849763     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2010.72     Document Type: Review

References (97)

1. Wingerchuk, D. M., Hogancamp, W. F., O'Brien, P. C. & Weinshenker, B. G. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53, 1107-1114 (1999).
2. de Seze, J. et al. Devic's neuromyelitis optica: clinical, laboratory, MRI and outcome profile. J. Neurol. Sci. 197, 57-61 (2002).
3. Jarius, S. et al. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat. Clin. Pract. Neurol. 4, 202-214 (2008).
4. Lucchinetti, C. F. et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125, 1450-1461 (2002).
5. Weinshenker, B. G. et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol. 46, 878-886 (1999).
6. Keegan, M. et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58, 143-146 (2002).
7. Lennon, v. A. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364, 2106-2112 (2004).
8. Lennon, v. A., Kryzer, T. J., Pittock, S. J., verkman, A. S. & Hinson, S. R. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202, 473-477 (2005).
9. Roemer, S. F. et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130, 1194-1205 (2007).
10. Misu, T. et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130, 1224-1234 (2007).
11. Weinshenker, B. G. et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann. Neurol. 59, 566-569 (2006).
12. Matiello, M. et al. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70, 2197-2200 (2008).
13. Takahashi, T. et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130, 1235-1243 (2007).
14. Jarius, S. et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131, 3072-3080 (2008).
15. Bonnan, M. et al. Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder. Mult. Scler. 15, 487-492 (2009).
16. Watanabe, S. et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult. Scler. 13, 128-132 (2007). (Pubitemid 46152772)
17. Nakashima, I. et al. Plasma exchange for neuromyelitis optica with aquaporin-4 antibody [abstract P04.092]. Neurology 72 (Suppl. 3), A187 (2009).
18. Cree, B. A. et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64, 1270-1272 (2005).
19. Jacob, A. et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol. 65, 1443-1448 (2008).
20. Bedi, G. S., Brown, A., Delgado, S., Usmani, N. & Sheremata, W. effect of rituximab on relapse rate and disability in neuromyelitis optica (NMO) [abstract P04.099]. Neurology 72 (Suppl. 3), A189 (2009).
21. Heerlein, K. et al. Aquaporin-4 antibody positive longitudinally extensive transverse myelitis following varicella zoster infection. J. Neurol. Sci. 276, 184-186 (2009).
22. Suzuki, C. et al. Anti-aquaporin-4 antibody production from peripheral B cells in neuromyelitis optica [abstract S39.005]. Neurology 72 (Suppl. 3), A281 (2009).
23. Meinl, e., Krumbholz, M. & Hohlfeld, R. B lineage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production, and therapeutic modulation. Ann. Neurol. 59, 880-892 (2006).
24. Sinclair, C., Kirk, J., Herron, B., Fitzgerald, U. & McQuaid, S. Absence of aquaporin-4 expression in lesions of neuromyelitis optica but increased expression in multiple sclerosis lesions and normal-appearing white matter. Acta Neuropathol. (Berl.) 113, 187-194 (2007).
25. Misu, T. et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J. Exp. Med. 209, 269-275 (2006).
26. Saadoun, S. et al. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133, 349-361 (2010).
27. Yanagawa, K. et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 73, 1628-1637 (2009).
28. Kale, N. et al. Humoral pattern II multiple sclerosis pathology not associated with neuromyelitis optica IgG. Arch. Neurol. 66, 1298-1299 (2009).
29. Misu, T. et al. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J. Neurol. Neurosurg. Psychiatry 80, 575-577 (2009).
30. Miyazawa, I. et al. High CSF neurofilament heavy chain levels in neuromyelitis optica. Neurology 68, 865-867 (2007).
31. Uzawa, A. et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J. Neurol. 256, 2082-2084 (2009).
32. Okada, K., Matsushita, T., Kira, J. & Tsuji, S. B-cell activating factor of the TNF family is upregulated in neuromyelitis optica. Neurology 74, 177-178 (2010).
33. Icoz, S. et al. enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. Int. J. Neurosci. 120, 71-75 (2010).
34. Alves-Leon, S. v. et al. Immune system markers of neuroinflammation in patients with clinical diagnose of neuromyelitis optica. Arq. Neuropsiquiatr. 66, 678-684 (2008).
35. Matsushita, T. et al. Aquaporin-4 autoimmune syndrome and anti-aquaporin-4 antibodynegative opticospinal multiple sclerosis in Japanese. Mult. Scler. 15, 834-847 (2009).
36. Correale, J. & Fiol, M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 63, 2363-2370 (2004).
37. Hinson, S. R. et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69, 2221-2231 (2007).
38. vincent, T. et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J. Immunol. 181, 5730-5737 (2008).
39. Hinson, S. R. et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by downregulating eAAT2. J. Exp. Med. 205, 2473-2481 (2008).
40. Kinoshita, M. et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem. Biophys. Res. Commun. 394, 205-210 (2010).
41. Zhou, J. et al. Altered blood-brain barrier integrity in adult aquaporin-4 knockout mice. Neuroreport 19, 1-5 (2008).
42. Zeng, X. N. et al. Aquaporin-4 deficiency downregulates glutamate uptake and GLT-1 expression in astrocytes. Mol. Cell. Neurosci. 34, 34-39 (2007).
43. Matute, C. et al. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci. 24, 224-230 (2001).
44. Alberdi, e. et al. Activation of kainate receptors sensitizes oligodendrocytes to complement attack. J. Neurosci. 26, 3220-3228 (2006).
45. Waters, P. et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch. Neurol. 65, 913-919 (2008).
46. Kalluri, S. R. et al. A novel bio-assay to determine and characterize the antibodies to aquaporin-4 [abstract P04.102]. Neurology 72 (Suppl. 3), A189 (2009).
47. Spiller, O. B., Moretto, G., Kim, S. U., Morgan, B. P. & Devine, D. v. Complement expression on astrocytes and astrocytoma cell lines: failure of complement regulation at the C3 level correlates with very low CD55 expression. J. Neuroimmunol. 71, 97-106 (1996).
48. Kinoshita, M. et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 20, 508-512 (2009).
49. Sabater, L. et al. Cytotoxic effect of neuromyelitis optica antibody (NMO-IgG) to astrocytes: an in vitro study. J. Neuroimmunol. 215, 31-35 (2009).
50. Hinson, S. R. et al. Prediction of neuromyelitis optica attack severity by quantitation of complement-mediated injury to aquaporin-4-expressing cells. Arch. Neurol. 66, 1164-1167 (2009).
51. Doi, H. et al. Hypercomplementemia at relapse in patients with anti-aquaporin-4 antibody. Mult. Scler. 15, 304-310 (2009).
52. Jarius, S., Franciotta, D., Bergamaschi, R., Wildemann, B. & Wandinger, K. P. Immunoglobulin M antibodies to aquaporin-4 in neuromyelitis optica and related disorders. Clin. Chem. Lab. Med. doi:10.1515/CCLM.2010.127.
53. Saikali, P., Cayrol, R. & vincent, T. Anti-aquaporin-4 auto-antibodies orchestrate the pathogenesis in neuromyelitis optica. Autoimmun. Rev. 9, 132-135 (2009).
54. Tani, T. et al. Identification of binding sites for anti-aquaporin 4 antibodies in patients with neuromyelitis optica. J. Neuroimmunol. 211, 110-113 (2009).
55. Nicchia, G. P. et al. Aquaporin-4 orthogonal arrays of particles are the target for neuromyelitis optica autoantibodies. Glia 57, 1363-1373 (2009).
56. Furman, C. S. et al. Aquaporin-4 square array assembly: opposing actions of M1 and M23 isoforms. Proc. Natl Acad. Sci. USA 100, 13609-13614 (2003).
57. Matiello, M. et al. Two different Arg19 mutations in the N-terminus of aquaporin-4 suggest a molecular mechanism for susceptibility to neuromyelitis optica [abstract S17.001]. Neurology 72 (Suppl. 3), A119 (2009).
58. Crane, J. M., Bennett, J. L. & verkman, A. S. Live cell analysis of aquaporin-4 M1/M23 interactions and regulated orthogonal array assembly in glial cells. J. Biol. Chem. 284, 35850-35860 (2009).
59. Jarius, S. et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J. Neurol. Sci. 291, 52-56 (2010).
60. Paul, F. et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med. 4, e133 (2007).
61. Marnetto, F. et al. Western blot analysis for the detection of serum antibodies recognizing linear aquaporin-4 epitopes in patients with neuromyelitis optica. J. Neuroimmunol. 217, 74-79 (2009).
62. Kinoshita, M. et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem. Biophys. Res. Commun. 386, 623-627 (2009).
63. Bradl, M. et al. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 66, 630-643 (2009).
64. Bennett, J. L. et al. Intrathecal pathogenic antiaquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 66, 617-629 (2009).
65. Nishiyama, S. et al. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 72, 1960-1961 (2009).
66. Jarius, S. et al. Neuromyelitis optica and longitudinally extensive transverse myelitis following thymectomy for myasthenia gravis [abstract P534]. Mult. Scler. 13 (Suppl. 2), S159 (2007).
67. Ahasan, H. A., Rafiqueuddin, A. K., Chowdhury, M. A., Azhar, M. A. & Kabir, F. Neuromyelitis optica (Devic's disease) following chicken pox. Trop. Doct. 24, 75-76 (1994).
68. Chusid, M. J., Williamson, S. J., Murphy, J. v. & Ramey, L. S. Neuromyelitis optica (Devic disease) following varicella infection. J. Pediatr. 95, 737-738 (1979).
69. Tran, C. et al. Neuromyelitis optica following CMv primo-infection. J. Intern. Med. 261, 500-503 (2007).
70. Ghezzi, A. et al. Clinical characteristics, course and prognosis of relapsing Devic's neuromyelitis optica. J. Neurol. 251, 47-52 (2004).
71. Jarius, S. et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 68, 1076-1077 (2007).
72. Weinshenker, B. G., Wingerchuk, D. M., Nakashima, I., Fujihara, K. & Lennon, v. A. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol. 5, 110-111 (2006).
73. Matsuoka, T. et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130, 1206-1223 (2007).
74. Takahashi, T. et al. establishment of a new sensitive assay for anti-human aquaporin-4 antibody in neuromyelitis optica. Tohoku J. Exp. Med. 210, 307-313 (2006).
75. Nakashima, I. et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J. Neurol. Neurosurg. Psychiatry 77, 1073-1075 (2006).
76. Petzold, A. et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J. Neurol. Neurosurg. Psychiatry 81, 109-111 (2010).
77. Takahashi, T. et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J. Neurol. Neurosurg. Psychiatry 79, 1075-1078 (2008).
78. Pittock, S. J. et al. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch. Neurol. 63, 964-968 (2006).
79. Magana, S. M. et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 72, 712-717 (2009).
80. Ito, S. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 73, 1604 (2009).
81. McKeon, A. et al. CNS aquaporin-4 autoimmunity in children. Neurology 71, 93-100 (2008).
82. Wandinger, K. P. et al. Autoantibodies against aquaporin-4 in patients with neuropsychiatric SLe and primary Sjrens syndrome. Arthritis Rheum. 62, 1198-1200 (2010).
83. Pittock, S. J. et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch. Neurol. 65, 78-83 (2008).
84. Hayakawa, S. et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J. Neuroimmunol. 196, 181-187 (2008).
85. Pittock, S. J. & Lennon, v. A. Aquaporin-4 autoantibodies in a paraneoplastic context. Arch. Neurol. 65, 629-632 (2008).
86. Cross, S. A. et al. Paraneoplastic autoimmune optic neuritis with retinitis defined by CRMP-5-IgG. Ann. Neurol. 54, 38-50 (2003).
87. Ducray, F. et al. Devic's syndrome-like phenotype associated with thymoma and anti-Cv2/CRMP5 antibodies. J. Neurol. Neurosurg. Psychiatry 78, 325-327 (2007).
88. Klawiter, e. C. et al. NMO-IgG detected in CSF in seronegative neuromyelitis optica. Neurology 72, 1101-1103 (2009).
89. Cree, B. A., Goodin, D. S. & Hauser, S. L. Neuromyelitis optica. Semin. Neurol. 22, 105-122 (2002).
90. Ho, J. D. et al. Crystal structure of human aquaporin 4 at 1.8 and its mechanism of conductance. Proc. Natl Acad. Sci. USA 106, 7437-7442 (2009).
91. Moreland, J. L., Gramada, A., Buzko, O. v., Zhang, Q. & Bourne, P. e. The Molecular Biology Toolkit (MBT): a modular platform for developing molecular visualization applications. BMC Bioinformatics 6, 21 (2005).
92. Adoni, T., Lino, A. M., Marchiori, P. e., Kok, F. & Callegaro, D. Seroprevalence of NMO-IgG antibody in Brazilian patients with neuromyelitis optica. Arq. Neuropsiquiatr. 66, 295-297 (2008).
93. Marignier, R. et al. NMO-IgG and Devic's neuromyelitis optica: a French experience. Mult. Scler. 14, 440-445 (2008).
94. Saiz, A. et al. Revised diagnostic criteria for neuromyelitis optica (NMO): application in a series of suspected patients. J. Neurol. 254, 1233-1237 (2007).
95. Bizzoco, e. et al. Prevalence of neuromyelitis optica spectrum disorder and phenotype distribution. J. Neurol. 256, 1891-1898 (2009).
96. Wingerchuk, D. M., Lennon, v. A., Pittock, S. J., Lucchinetti, C. F. & Weinshenker, B. G. Revised diagnostic criteria for neuromyelitis optica. Neurology 66, 1485-1489 (2006).
97. Apiwattanakul, M. et al. AQP4-IgG immunoprecipitation assay optimization. Clin. Chem. 55, 592-594 (2009).